Clinical Research Directory
Browse clinical research sites, groups, and studies.
9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Summary
This is a randomized, controlled, open-label, multicenter phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of 9MW2821 combined with Toripalimab versus standard chemotherapy in first-line locally advanced or metastatic urothelial cancer.
Official title: A Randomized, Controlled, Open-label, Multicenter Phase 3 Clinical Study of 9MW2821 in Combination With Toripalimab Versus Standard Chemotherapy in First-line Locally Advanced or Metastatic Urothelial Cancer
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
460
Start Date
2024-08-22
Completion Date
2028-12
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Interventions
9MW2821
9MW2821, 1.25mg/kg, intravenous (IV) infusion
Toripalimab
Toripalimab, 240mg, intravenous (IV) infusion
Gemcitabine
Gemcitabine: 1000mg/m2, intravenous (IV) infusion
Cisplatin/Carboplatin
Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China